Greenway KT

Lady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.

17 papers · ORCID

ArticlePsilocybin

Defining 'psychedelic'.

Ostrand AE, Nour MM, Timmermann C +7

Europe PMC2026
ArticleDMT

Computational spirits: a neuroscientific account of psychedelic entity encounters.

Mago J, Deane G, Sandved-Smith L +7

Europe PMC2026
ArticleKetamine

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

Agnorelli C, Peill J, Sawicka G +18

Europe PMC2026
ArticleKetamine

A long, strange trip: Ketamine treatment in psychiatry.

Nutt DJ, Morgan C, Erritzoe D +2

Europe PMC2025
ArticleKetamine

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.

Greenway KT, Garel N, Dinh-Williams LL +9

Europe PMC2026
ArticlePsychedelics

An international Delphi consensus for reporting of setting in psychedelic clinical trials.

Pronovost-Morgan C, Greenway KT, Roseman L

Europe PMC2025
ArticleKetamine

The ketamine chameleon: history, pharmacology, and the contested value of experience.

Diep D, de la Salle S, Thibault Lévesque J +3

Europe PMC2025
ArticlePsychedelics

Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics.

Gloeckler SG, Lehmann A, de la Salle S +2

Europe PMC2024
ArticlePsilocybin

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.

Erritzoe D, Barba T, Greenway KT +9

Europe PMC2024
ArticlePsilocybin

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.

de la Salle S, Kettner H, Thibault Lévesque J +8

Europe PMC2024
ArticlePsilocybin

Psychedelics and the 'inner healer': Myth or mechanism?

Peill J, Marguilho M, Erritzoe D +5

Europe PMC2024
ArticleKetamine

Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program.

Manson E, Ryding E, Taylor W +6

Europe PMC2023
ArticleKetamine

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression.

Garel N, Drury J, Thibault Lévesque J +9

Europe PMC2023
ArticleKetamine

Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings.

Garel N, Thibault Lévesque J, Sandra DA +5

Europe PMC2023
ArticlePsilocybin

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.

Gobbi G, Inserra A, Greenway KT +2

Europe PMC2022
ArticlePsilocybin

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

Rosenblat JD, Husain MI, Lee Y +18

Europe PMC2023
ArticlePsilocybin

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.

Greenway KT, Garel N, Jerome L +1

Europe PMC2020